MGD010 + hepatitis A vaccine

MGD010 + hepatitis A vaccine is an experimental combination therapy consisting of **MGD010**, a humanized bispecific monoclonal antibody designed to modulate B-cell function by simultaneously targeting CD32B and CD79B, administered together with a hepatitis A vaccine for immunologic evaluation. MGD010 utilizes the DART (Dual-Affinity Re-Targeting) platform to deliver a co-inhibitory signal that suppresses B-cell activation without causing B-cell depletion, with the intent of reducing pathogenic antibody production in autoimmune disorders. In clinical studies, the hepatitis A vaccine is used in combination to assess MGD010’s impact on immune modulation and vaccine response in healthy subjects[2][4][5].